Anhui Fengyuan Pharmaceutical Co., Ltd. (SHE:000153)
China · Delayed Price · Currency is CNY 5.43
+0.14 (2.65%)
Jul 3, 2026, 3:04 PM CST
SHE:000153 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 3,689 | 3,794 | 4,196 | 4,177 | 3,931 | 3,603 |
Other Revenue | 64.01 | 64.01 | 89.04 | 98.88 | 73.24 | 49.3 |
| 3,753 | 3,858 | 4,285 | 4,275 | 4,004 | 3,652 | |
Revenue Growth (YoY) | -8.56% | -9.95% | 0.21% | 6.78% | 9.63% | 9.97% |
Cost of Revenue | 3,069 | 3,159 | 3,357 | 3,185 | 2,885 | 2,572 |
Gross Profit | 683.88 | 699.15 | 927.3 | 1,091 | 1,119 | 1,081 |
Selling, General & Admin | 474.44 | 478.05 | 650.91 | 781.9 | 847.27 | 816.65 |
Research & Development | 38.13 | 48.94 | 63.13 | 77.02 | 65.47 | 76.02 |
Other Operating Expenses | 30.27 | 25.79 | 33.96 | 37.58 | 32.1 | 30.31 |
Operating Expenses | 559.6 | 568.54 | 755.39 | 897.19 | 949.35 | 924.51 |
Operating Income | 124.28 | 130.61 | 171.91 | 193.62 | 169.83 | 156.05 |
Interest Expense | -34.16 | -35.2 | -30.36 | -33.89 | -32.87 | -39.26 |
Interest & Investment Income | 12.65 | 11.62 | 11.4 | 14.05 | 9.1 | 4.27 |
Currency Exchange Gain (Loss) | 0.3 | 0.3 | 0.11 | 0.14 | 0.48 | -0.35 |
Other Non Operating Income (Expenses) | -3.91 | -3.42 | -3.29 | 2.44 | -2.23 | 0.8 |
EBT Excluding Unusual Items | 99.17 | 103.92 | 149.78 | 176.36 | 144.31 | 121.52 |
Impairment of Goodwill | -3.26 | -3.26 | - | - | - | -3.59 |
Gain (Loss) on Sale of Investments | 0.61 | -3.61 | -5.28 | -6.92 | 11.08 | 9.4 |
Gain (Loss) on Sale of Assets | -0.44 | -0.33 | -1.61 | 4.38 | -0.25 | -0.51 |
Asset Writedown | -0.63 | -0.92 | -0.01 | -0.28 | -0.01 | -4.98 |
Other Unusual Items | 30.05 | 29.38 | 65.84 | 41.35 | 47.16 | 38 |
Pretax Income | 125.49 | 125.18 | 208.72 | 214.89 | 202.29 | 159.83 |
Income Tax Expense | 31.58 | 30.38 | 51.07 | 57.6 | 51.35 | 41.98 |
Earnings From Continuing Operations | 93.91 | 94.8 | 157.65 | 157.3 | 150.94 | 117.86 |
Minority Interest in Earnings | 4.49 | 4.61 | 3.18 | 1.99 | 3.49 | 5.13 |
Net Income | 98.4 | 99.42 | 160.83 | 159.29 | 154.43 | 122.98 |
Net Income to Common | 98.4 | 99.42 | 160.83 | 159.29 | 154.43 | 122.98 |
Net Income Growth | -35.20% | -38.19% | 0.97% | 3.15% | 25.57% | 18.57% |
Shares Outstanding (Basic) | 465 | 465 | 465 | 465 | 444 | 437 |
Shares Outstanding (Diluted) | 465 | 465 | 465 | 465 | 444 | 437 |
Shares Change (YoY) | 0.03% | 0.01% | -0.05% | 4.71% | 1.59% | 0.03% |
EPS (Basic) | 0.21 | 0.21 | 0.35 | 0.34 | 0.35 | 0.28 |
EPS (Diluted) | 0.21 | 0.21 | 0.35 | 0.34 | 0.35 | 0.28 |
EPS Growth | -35.22% | -38.20% | 1.02% | -1.49% | 23.60% | 18.53% |
Free Cash Flow | -42.92 | -101.31 | -17.78 | 102.64 | 358.23 | 104.78 |
Free Cash Flow Per Share | -0.09 | -0.22 | -0.04 | 0.22 | 0.81 | 0.24 |
Dividend Per Share | 0.100 | 0.100 | 0.100 | 0.107 | 0.071 | 0.071 |
Dividend Growth | - | - | -6.63% | 50.00% | - | - |
Gross Margin | 18.22% | 18.12% | 21.64% | 25.51% | 27.95% | 29.59% |
Operating Margin | 3.31% | 3.38% | 4.01% | 4.53% | 4.24% | 4.27% |
Profit Margin | 2.62% | 2.58% | 3.75% | 3.73% | 3.86% | 3.37% |
Free Cash Flow Margin | -1.14% | -2.63% | -0.41% | 2.40% | 8.95% | 2.87% |
EBITDA | 250.28 | 251.57 | 272.7 | 294.51 | 263.38 | 241.66 |
EBITDA Margin | 6.67% | 6.52% | 6.37% | 6.89% | 6.58% | 6.62% |
D&A For EBITDA | 126 | 120.96 | 100.79 | 100.89 | 93.55 | 85.61 |
EBIT | 124.28 | 130.61 | 171.91 | 193.62 | 169.83 | 156.05 |
EBIT Margin | 3.31% | 3.38% | 4.01% | 4.53% | 4.24% | 4.27% |
Effective Tax Rate | 25.17% | 24.27% | 24.47% | 26.80% | 25.39% | 26.26% |
Revenue as Reported | 3,753 | 3,858 | 4,285 | 4,275 | 4,004 | 3,652 |